GlassScriptPhysician profile
Abdus Lakhani
NPI 1831187244
$2,611.21
in general payments reported to CMS, 2019-2025
33 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $153 · 2021: $667 · 2022: $417 · 2023: $514 · 2024: $335 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.48 | 2021-2025 | |
| Novo Nordisk INC | $413.97 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $196.47 | 2019-2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $141.98 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $128.21 | 2019-2025 | Spravato |
| Smith+Nephew, INC. | $125.90 | 2021-2023 | Grafix Pl, Stravix, Grafix |
| Abbott Laboratories | $117.04 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $75.39 | 2019-2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $66.05 | 2019-2021 | |
| Medline Industries LP | $64.99 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $60.11 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $59.27 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $45.53 | 2024 | Ingrezza |
| Pfizer INC. | $42.47 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.20 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $35.92 | 2021 | |
| Antares Pharma, INC. | $34.71 | 2024-2025 | Xyosted |
| Kerecis Limited | $31.42 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Sanofi-Aventis U.S. LLC | $30.08 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.01 | 2021 | |
| Paratek Pharmaceuticals, INC. | $29.67 | 2021 | |
| Integra Lifesciences Corporation | $28.46 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| E.R. Squibb & Sons, L.L.C. | $27.82 | 2022-2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $27.51 | 2021 | |
| Mylan Specialty L.P. | $22.83 | 2023 | Yupelri |
| Mycovia Pharmaceuticals, INC. | $17.38 | 2023 | Vivjoa |
| Organogenesis INC. | $17.16 | 2020 | |
| Amgen INC. | $16.04 | 2023 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $15.47 | 2022 | |
| Kci USA, INC. | $15.14 | 2020 | |
| Astellas Pharma US INC | $14.00 | 2019 | |
| Glaxosmithkline, LLC. | $12.80 | 2020 | |
| Allergan, INC. | $10.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdus Lakhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.